19 March 2024
19 March 2024
Lenmeldy utilises the genetically modified haematopoietic stem cells of the patient to halt disease progression.
BMS has acquired Karuna's lead asset, KarXT (xanomeline-trospium), along with its early-stage and pre-clinical pipeline.
AdCom voted eight to three in favour of BMS and 2seventy bio’s CAR-T cell therapy, Abecma, in triple-class exposed multiple myeloma patients.
The initiative will offer pharmaceutical companies new opportunities to execute innovations in clinical research.
The approval is based on the outcomes of a multicentre, single-arm Phase II registrational clinical trial in China.
Fennec’s Pedmarqsi/Pedmark is the only approved therapy to treat cisplatin-induced hearing loss in paediatric cancer patients.
Rising numbers of counterfeit drugs are entering pharmaceutical supply chains, necessitating advanced track-and-trace systems.
Using GlobalData’s Price Intelligence (POLI) & HTA database, analysis has been conducted that will provide insight into how the HTA landscape adapted between 2019 and 2023.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
